Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kendle Acquires Charles River Labs' Phase II-IV Services | Contract Pharma

What are you searching for?

Sign in
Breaking News

Kendle Acquires Charles River Labs’ Phase II-IV Services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kendle will acquire the Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. for approximately $215 million in cash. The move will strengthen Kendle’s position in the clinical development industry, adding therapeutic expertise, diversifying its customer base and expanding its capacity for global trials. The transaction is expected to close in the third quarter of 2006. The acquired operations will operate under the Kendle name.

“We are excited by this move, which is an important component of our overall growth strategy designed to significantly enhance our global competitive position and accelerate Kendle to a $500 million organization,” said Candace Kendle, Pharm.D., Kendle’s chairman and chief executive officer. “Our customers will benefit from our strengthened global project leadership capability, expanded therapeutic expertise in the fastest-growing areas of clinical development and enhanced depth in North America and a number of key European markets. We look forward to completing the integration of our new operations into Kendle under our four service brands, and adding value for our customers through our combined organization.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters